OnKure Therapeutics

OKUR

Market cap $37.6M

-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with trastuzumab and tucatinib in HER2+ metastatic breast cancer -- Cash position of $83.4M expected to provide cash runway into Q4 2026 BOULDER, Colo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the second quarter ended June 30, 2025 and provided a business update.

-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data

— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024

BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D.

-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported

Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT

OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET

Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-219 has 80X fold improved selectivity PI3K-a targeting versus wild-type PI3K-a, potentially allowing for higher dosing and reducing unwanted off-target effects. The merger with Reneo Pharmaceuticals and $65 million private placement boosts OnKure's cash to $139 million, funding operations into Q4 2026.